Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Hexarelin binds the GHS-R1a (ghrelin) , triggering pulsatile growth hormone release that is largely independent of, and synergistic with, signalling. Literature also describes interactions with the cardiac CD36 receptor in animal models.
02
Research applications
- Growth hormone secretion pharmacology
- Rodent cardiovascular and metabolic models
- GHRP comparison studies
- Aging and metabolic-syndrome research
Evidence at a glance
What's behind this profile
3 citations · 1997–2017
- Human
- 1
- Animal
- 1
- Review
- 1
Studies in human volunteers or patients (incl. early-phase trials).
Studies in rodents or other animal models.
Narrative or systematic reviews; no primary data.
Publication years
- 97
- 98
- 99
- 00
- 01
- 02
- 03
- 04
- 05
- 06
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Interaction of the growth hormone releasing peptide hexarelin with somatostatin
1997
Massoud AF et al. · Clinical Endocrinology
- Model
- Human pharmacology — controlled infusion study in adult volunteers
- Sample
- n=12
Reported that hexarelin counteracted somatostatin-induced GH suppression and showed synergistic GH-releasing activity when combined with .
Growth hormone-releasing peptides
1997
Ghigo E et al. · European Journal of Endocrinology
- Model
- Narrative review covering GHRP-6, GHRP-1, GHRP-2, and hexarelin
- Sample
- N/A (review)
Reviewed GHRP pharmacology, concepts, and clinical applications in growth-hormone hyposecretory states across the GHRP family.
Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice
2017
Mosa R et al. · Endocrinology
- Model
- In vivo — insulin-resistant MKR mice
- Sample
- Not reported in abstract
Hexarelin treatment was associated with improved glucose tolerance, lowered triglycerides, enhanced adipocyte differentiation, and corrected body composition in the mouse model used.
Evidence caveats
- Hexarelin is not approved as a medicine. Human pharmacology evidence is limited to small early-phase studies.
- Most efficacy data outside GH-pharmacology come from rodent models; extrapolation to clinical outcomes is not established.
04
Storage and handling
Store under controlled laboratory conditions with batch and preparation details recorded.
- Maintain batch and supplier documentation for and comparison studies.
- Avoid repeated cycles where not protocol-supported.
- Research-only inventory must be clearly separated from any clinical material.